CRBP vs. SANA, FULC, ABVX, RAPP, ATAI, URGN, ORIC, MREO, BNTC, and TKNO
Should you be buying Corbus Pharmaceuticals stock or one of its competitors? The main competitors of Corbus Pharmaceuticals include Sana Biotechnology (SANA), Fulcrum Therapeutics (FULC), ABIVAX Société Anonyme (ABVX), Rapport Therapeutics (RAPP), Atai Life Sciences (ATAI), UroGen Pharma (URGN), ORIC Pharmaceuticals (ORIC), Mereo BioPharma Group (MREO), Benitec Biopharma (BNTC), and Alpha Teknova (TKNO). These companies are all part of the "pharmaceutical products" industry.
Corbus Pharmaceuticals vs.
Corbus Pharmaceuticals (NASDAQ:CRBP) and Sana Biotechnology (NASDAQ:SANA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, profitability, dividends, analyst recommendations, institutional ownership, valuation, risk, earnings and media sentiment.
Corbus Pharmaceuticals' return on equity of -42.28% beat Sana Biotechnology's return on equity.
In the previous week, Sana Biotechnology had 15 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 20 mentions for Sana Biotechnology and 5 mentions for Corbus Pharmaceuticals. Corbus Pharmaceuticals' average media sentiment score of 1.15 beat Sana Biotechnology's score of 0.06 indicating that Corbus Pharmaceuticals is being referred to more favorably in the media.
Corbus Pharmaceuticals has a beta of 3.19, indicating that its stock price is 219% more volatile than the S&P 500. Comparatively, Sana Biotechnology has a beta of 1.75, indicating that its stock price is 75% more volatile than the S&P 500.
Sana Biotechnology is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Corbus Pharmaceuticals presently has a consensus price target of $50.88, suggesting a potential upside of 586.57%. Sana Biotechnology has a consensus price target of $10.80, suggesting a potential upside of 451.02%. Given Corbus Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Corbus Pharmaceuticals is more favorable than Sana Biotechnology.
Corbus Pharmaceuticals received 435 more outperform votes than Sana Biotechnology when rated by MarketBeat users. Likewise, 67.20% of users gave Corbus Pharmaceuticals an outperform vote while only 64.86% of users gave Sana Biotechnology an outperform vote.
64.6% of Corbus Pharmaceuticals shares are held by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are held by institutional investors. 3.6% of Corbus Pharmaceuticals shares are held by company insiders. Comparatively, 30.1% of Sana Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Corbus Pharmaceuticals beats Sana Biotechnology on 11 of the 16 factors compared between the two stocks.
Get Corbus Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRBP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Corbus Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:CRBP) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy CRBP Stock Free CRBP Stock Alerts